Joseph Sassine

Incidence and risk factors for musculoskeletal adverse effects associated with daptomycin in patients receiving outpatient parenteral antimicrobial therapy | Antimicrobial Stewardship & Healthcare Epidemiology | Cambridge Core Incidence and risk factors for musculoskeletal adverse effects associated with daptomycin in patients receiving outpatient parenteral antimicrobial therapy - Volume 5 Issue 1

@bryanpwhite.bsky.social et al: In a cohort (n=127) of OPAT patients on daptomycin 7.4 mg/kg for an average of 37 days, the rate of CK elevation was 11.8% at a median of 13 days (IQR 9-16) supporting weekly lab monitoring on daptomycin for OPAT. doi.org/10.1017/ash....

This study offers real-world data evaluating the ePlex BCID-FP rapid identification system for yeast and found it was less sensitive than previously reported and infrequently led to de-escalation of antifungals
doi.org/10.1093/jaca...
@josephsassinemd.bsky.social #JACAMRNews #IDSKy

ID fellowship applicants, make sure to check out our program @ou.edu:
2 year clinical program - 3 tracks (TxID, hosp epi, trop med) - Path for crit care fellowship - 12 credit certificates in year 2

#TxID #IDSky #MedEd

medicine.ouhsc.edu/academic-dep...

We don’t, because this panel is meant to identify fungi on blood culture specimens exclusively.

Evaluation of a rapid identification panel for fungemia Abstract. Bloodstream infections due to yeast are associated with a high mortality rate. There is a lack of data that evaluate the real-world sensitivity o

Out now in @jac-amr.bsky.social, our real world analysis of BCID fungal panel for diagnosis of fungemia, led by the great Emily Siegrist - Sensitivity of 94%, lower than anticipated
@bryanpwhite.bsky.social @ritawilson.bsky.social
#IDSky
academic.oup.com/jacamr/artic...

And part 2 is out now: How to prevent travel-related infections in the transplant recipient, check it out!
@ritawilson.bsky.social @andhen25.bsky.social
#IDSky #TxID

journals.sagepub.com/doi/full/10....

Invasive fusariosis after CD19 chimeric antigen receptor T-cell therapy | ASM Case Reports Invasive fusariosis is a rare entity that primarily affects patients with hematological malignancies and recipients of hematopoietic cell transplants. Cases of mold infections in chimeric antigen receptor T-cell (CAR-T) therapy recipients have seldom been reported (1–6). We herein present this case of invasive fusariosis managed with combination antifungal therapy. Additionally, we provide a succinct review of cases reported in existing literature.

Invasive fusariosis after CAR T is rare but can be consequential. Here’s our case of cutaneous fusariosis after CD19 CAR T, with @ritawilson.bsky.social @ouholter.bsky.social and others, out in @asm.org Case Reports!
#TxID

journals.asm.org/doi/10.1128/...

Had a great time in Syracuse presenting Medicine Grand Rounds earlier today on Infections after CAR T at SUNY Upstate and meeting some great ID colleagues there!
#TxID

These tracks were only possible thanks to the diverse expertise of our faculty (physicians & pharmacists), support from our section chief, close collaboration with BMT, SOT, PCCM!
@bryanpwhite.bsky.social @ritawilson.bsky.social

4. ID/critical care track
- 2 years of ID fellowship with a pathway for 3rd year in critical care medicine
- Close collaboration with PCCM division
- Travel to ID or CCM conferences
- We cover certificate in healthcare admin, population health or clinical/translational science

3. Trop Med/Global Health Track
- 8 months of research
- 1 month international rotation
- Travel to trop med conferences
- Year 2 clinic - Travel medicine, refugee health
- We cover one of the above certificates or trop med diploma from ASTM&H or ISTM

2. Hospital epi/Healthcare admin Track
- 2 months of ASP, IP and OPAT rotations
- Year 2 clinic - General ID, OPAT clinics
- 7 months of research/QI
- Travel to ASP/IP conferences
- We cover certificate in healthcare admin, population health or clinical/translational science

1. TxID Track
- 10 months of TxID inpatient consults
- 1 month of inpatient BMT & SOT
- Year 2 clinic - Heme/TCT ID and SOT ID
- 9 months of TxID research
- Travel to TxID conferences
- We cover certificate in healthcare admin, population health or clinical/translational science

Excited to launch new tracks in our 2-year ID fellowship program @ou.edu starting July 2025: TxID, Hospital epi/healthcare admin, Trop Med/Global Health, ID/Crit Care.
Tracks come with option for 12-credit certificates, covered by the program:

medicine.ouhsc.edu/academic-dep...

🧵

#IDSky #TxID

Sage Journals: Discover world-class research Subscription and open access journals from Sage, the world's leading independent academic publisher.

How to prevent infections in the increasingly immunocompromised traveler? Part 1 (non-transplant) is out now! Stay tuned for part 2!
@ritawilson.bsky.social @andhen25.bsky.social @ou.edu
#IDSky #TxID

journals.sagepub.com/doi/10.1177/...

Herpesvirus Infections After Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies: A Review In this narrative review, we explore the burden and risk factors of various herpesvirus infections in patients receiving chimeric antigen receptor T-cell (CAR-T) therapy or bispecific antibodies (BsAb...

Out now, everything you need to know, that is known and not known, about herpesviruses after CAR T and BsAb, in our review with Dr Emily Siegrist and Dr Roy Chemaly!
@mdanderson.bsky.social @ou.edu
#IDSky #TxID

www.mdpi.com/1999-4915/17...

How Oklahomans can protect themselves from norovirus, or 'stomach bug' A stomach bug sweeping the country has infected hundreds of patients in its path.

Spoke to @koconews.bsky.social about norovirus, clinical presentation and preventive measures #IDSky

www.koco.com/article/okla...

We have used it a couple times for VRE where no other options were available or feasible @bryanpwhite.bsky.social

T-SPOT.TB performs much better in many immunocompromised populations IMO, but historically was logistically more difficult from CA due to time-sensitive FedEx of samples to Memphis which failed a lot with winter storms. Less an issue now that Quest bought T-SPOT.

T-SPOT resulted in
- fewer indeterminate results (than QFT)
- more “actionable” results (than QFT)

in certain immunocompromised populations #TBSky

Out now in @thetxidjournal.bsky.social!

T-SPOT.TB is more likely to produce actionable results than QFT-TB in patients with cancer being screened for latent TB.

#TxID #IDSky

onlinelibrary.wiley.com/doi/10.1111/...

Risk factors for positive follow-up blood cultures in critically ill adults with Gram-negative bacteraemia AbstractObjectives. To evaluate the utility of follow-up blood cultures (FUBCs) for Gram-negative bloodstream infection (BSI) in ICU patients and identify

A retrospective cohort study of Gram-negative BSIs in ICU shows fever, lack of source control and time to repeat follow-up blood culture (FUBC) as risk factors for repeat positive FUBC:
https://doi.org/10.1093/jacamr/dlae144
#JACAMRNews @bryanpwhite.bsky.social

A5. Another test I am using more often is the CMV T-cell immunity panel through Viracor, especially to help with duration of secondary prophylaxis, particularly in the non-HCT, non-SOT cases where risk period and duration of prophylaxis are still unknown. #TxID

A5. I focused my use of Karius for pneumonia in those patients who cannot have a BAL, based on the PICKUP study where this subset showed the highest additive diagnostic yield. Has been a mixed experience overall. #TxID

And our editorial

www.clinicalmicrobiologyandinfection.com/article/S119...

Special theme issue in @cmijournal.bsky.social - Infections in immunocompromised hosts, edited by Dr Roy Chemaly, with a series of high yield #TxID reviews, including our review of herpesviruses after allogeneic HCT #IDSky

www.clinicalmicrobiologyandinfection.com/article/S119...

Remote therapeutic monitoring reduces readmissions, academic research shows The University of Oklahoma College of Medicine did a controlled test and showed the odds of infection-related readmissions were decreased in the RTM group by 76% at 30 days, 80% at 60 days and 68% at ...

Recently spoke with Health IT News about the results of our innovative trial of remote therapeutic monitoring in OPAT, how RTM helped us reduce infection-related readmissions and improve patient adherence to IV ABx #IDSky #OPAT
@ou.edu

www.healthcareitnews.com/news/remote-...

Check out our most recent work - A large database analysis of viral and fungal infections after CAR T cell therapy, published at @cmijournal.bsky.social, with @andhen25.bsky.social #IDSky #TxID

www.clinicalmicrobiologyandinfection.com/article/S119...

First post on #IDSky

We have an ID fellowship opening at the University of Oklahoma @ou.edu, starting July 2025.

Two-year program, with great exposure to HIV, transplant ID and surgical infections, and above all, great people to train with!

DM me for details!

medicine.ouhsc.edu/academic-dep...